Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Biogen Acquires Rights to Bio-Thera RA Biosimilar for $30 Million Upfront

publication date: Apr 8, 2021

Biogen, a Cambridge, MA biopharma, in-licensed ex-China rights to a biosimilar aimed at rheumatoid arthritis from Guangzhou's Bio-Thera. The candidate, BAT1806, is a proposed biosimilar to Roche's Actemra® (tocilizumab). It is an anti-interleukin-6 (IL-6) receptor mAb that is currently in Phase III trials. Biogen will make a $30 million upfront payment once BAT1806 reports satisfactory Phase III results, plus unspecified milestones and royalties. More details....

Stock Symbols: (NSDQ: BIIB) (SHA: 688177)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.